Shan-Tan Kidney Stone Centre Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 0.12 M
- Company Age 26 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -17.52%
- Profit Growth 784.53%
- Ebitda 189.55%
- Net Worth 87.82%
- Total Assets 15.91%
About Shan-Tan Kidney Stone Centre
Shan-Tan Kidney Stone Centre Private Limited (SKSCPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 September 1998 and has a history of 26 years and five months. Its registered office is in Thanjavur, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Balasubramanian Shanmugam, Vijay Balasubramanian, and Usha Balasubramanian serve as directors at the Company.
Company Details
-
Location
Thanjavur, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85110TN1998PTC041096
-
Company No.
041096
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Sep 1998
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Shan-Tan Kidney Stone Centre?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balasubramanian Shanmugam
|
Director | 08-Sep-1998 | Current |
|
Vijay Balasubramanian
|
Director | 08-Sep-1998 | Current |
|
Usha Balasubramanian
|
Director | 08-Sep-1998 | Current |
Financial Performance of Shan-Tan Kidney Stone Centre.
Shan-Tan Kidney Stone Centre Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 17.52% decrease. The company also saw a substantial improvement in profitability, with a 784.53% increase in profit. The company's net worth Soared by an impressive increase of 87.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shan-Tan Kidney Stone Centre?
In 2017, Shan-Tan Kidney Stone Centre had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sb Cardio Vascular Centre Private LimitedBalasubramanian Shanmugam and Vijay Balasubramanian are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shan-Tan Kidney Stone Centre?
Unlock and access historical data on people associated with Shan-Tan Kidney Stone Centre, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shan-Tan Kidney Stone Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shan-Tan Kidney Stone Centre's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.